(Q48949989)

English

Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin β1-driven Src-Akt bypass signaling

scientific article published on 31 October 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/27797376

Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin β1-driven Src-Akt bypass signaling (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/27797376

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

invasive ductal carcinoma

1 reference

based on heuristic

inferred from title

pancreatic ductal adenocarcinoma

1 reference

based on heuristic

inferred from title

pancreatic ductal carcinoma

1 reference

based on heuristic

inferred from title

author name string

Y-J Kim

1

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/27797376

K Jung

2

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/27797376

D-S Baek

3

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/27797376

S-S Hong

4

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/27797376

Y-S Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/27797376

language of work or name

0 references

publication date

31 October 2016

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/27797376

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/27797376

36

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/27797376

18

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/27797376

2543-2552

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/27797376

Pancreatic cancer: from state-of-the-art treatments to promising novel therapies

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

The quest to overcome resistance to EGFR-targeted therapies in cancer

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Epidermal growth factor receptor in pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Understanding resistance to EGFR inhibitors-impact on future treatment strategies

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Neuropilins are multifunctional coreceptors involved in tumor initiation, growth, metastasis and immunity

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Neuropilin Functions as an Essential Cell Surface Receptor

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Tumor-penetrating iRGD peptide inhibits metastasis

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Enhancement of the tumor penetration of monoclonal antibody by fusion of a neuropilin-targeting peptide improves the antitumor efficacy

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Aberrant expression of neuropilin-1 and -2 in human pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Neuropilin-1/GIPC1 signaling regulates alpha5beta1 integrin traffic and function in endothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Neuropilin-1 interacts with integrin beta1 and modulates pancreatic cancer cell growth, survival and invasion

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Distinct effects of β1 integrin on cell proliferation and cellular signaling in MDA-MB-231 breast cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Yes and Lyn play a role in nuclear translocation of the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Distinct recycling of active and inactive β1 integrins

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Integrin traffic - the update

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Talin Binding to Integrin ß Tails: A Final Common Step in Integrin Activation

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Reconstruction of integrin activation

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Drugging the undruggable RAS: Mission possible?

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Neuropilin-1 stimulates tumor growth by increasing fibronectin fibril assembly in the tumor microenvironment

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Protein kinase LKB1 promotes RAB7-mediated neuropilin-1 degradation to inhibit angiogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

A general strategy for generating intact, full-length IgG antibodies that penetrate into the cytosol of living cells

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

CXCR4 function requires membrane cholesterol: implications for HIV infection

1 reference

https://api.crossref.org/works/10.1038%2FONC.2016.407

21 January 2018

Identifiers

10.1038/ONC.2016.407

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/27797376

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/27797376

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48949989&oldid=2216556296"